



Targeting Cell Metabolism as Cancer Therapy

Collection Editor:

Dr. Veronique Baud

1. NF- κ B, Differentiation and
Cancer, University Paris
Descartes, Sorbonne Paris Cité,
75014 Paris, France
2. Faculté de Pharmacie, 4
Avenue de l'Observatoire, 75006
Paris, France

Message from the Collection Editor

Dear Colleagues,

Reprogramming of energy metabolism in cancer has recently been recognized as one of the hallmarks of cancer and its understanding will contribute to the development of new anticancer strategies and/or improve the effectiveness of existing therapies.

This Topical Collection aims to publish research on the metabolic features of solid and hematological cancers, including cancer cells and the tumor microenvironment, and how to exploit the metabolic perturbations to develop new anticancer treatments.

We invite research and review papers covering all aspects of cancer cell metabolism and related innovative cancer therapies. Topics include, but are not limited to, fundamental understanding of metabolic disturbance in cancer, associated gene expression profiling, epigenetic regulation, metabolomics, diagnostic and prognostic biomarkers, molecular targets, cancer drug development targeting metabolism, clinical trials with new agents, and validation in animal models.

Dr. Veronique Baud
Collection Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)